CJC 1295 with DAC
CJC-1295 with DAC is a tetrasubstituted 30-amino acid long peptide hormone, functioning as a growth hormone releasing hormone (GHRH). Synthetic GHRH had previously been discovered, but the half-life was very short. This is where the development of CJC-1295 with DAC began, in search for a longer half-life for great efficacy.
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-LysLys(Maleimidopropionyl)-NH2 (Drug Affinity Complex)
Molecular formula: C165H269N47O46
Molar Mass: 3647.15
CAS number: 863288-34-0
The CJC-1295 DAC Structure
Buy CJC-1295 DAC Now
The function of CJC 1295 DAC
The function of CJC 1295 DAC is related to the active agent in the peptide chain GHRH1-29, which plays an important role in providing stable and stable level for the experimental subjects. Specifically, CJC 1295 combined with DAC can significantly prolong the fast half-life of GHRH1-29, thus providing more effective steady-state means for animal experiments. The function of the peptide was also determined to prevent programmed cell death, increase fat decomposition rate and increase biological activity.
Hypothetical Benefits of CJC 1295 DAC
The overall function of CJC 1295 DAC has led to scientific research based on animal experimental subjects to determine that polypeptides may be the source of a large number of theoretical benefits. These benefits are mostly related to increased protein synthesis, which is directly related to the ability of peptides to significantly prolong the half-life of GHRH1-29. These related benefits include increased bone mineral density, more effective weight loss methods, increased muscle tissue proliferation and faster recovery from injury.
Reserved for scientific research
It should be emphasized that although a great deal of research and research has been done to identify the function and mechanics of CJC 1295 DAC, at this time, it is only for the sole purpose of scientific research. Any findings or observations related to CJC 1295, as well as the overall functional, mechanical or theoretical advantages of DAC, should be exclusive to laboratories, medical research institutions or another strictly controlled environment in the vein.
Various experiments were performed in the CJC 1295 DAC in vivo pharmacokinetics and clinical endocrinology and metabolism reported that a dose-dependent increase means that the plasma GH concentration is 2 – 10 times more than 6 days, and the igf – 1 concentration is increased by 1.5. – 3 fold for 9 – 11 days after an injection. The mean half-life was 5.8-8.1 days, and the average IGF-1 level remained above baseline for up to 28 days after multiple doses. There were no reports of serious adverse reactions in each group.